Trial Profile
Exenatide for Myocardial Protection During Reperfusion Study: A Double-blind, Placebo-controlled Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Myocardial infarction; Myocardial reperfusion injury
- Focus Therapeutic Use
- Acronyms EMPRES
- 03 Aug 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.
- 03 Aug 2016 Planned primary completion date changed from 1 Jul 2016 to 1 Jul 2017.
- 26 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Jan 2017 as reported by ClinicalTrials.gov record.